Richard S. Levy - 03 May 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
03 May 2024
Net transactions value
$0
Form type
4
Filing time
07 May 2024, 16:46:15 UTC
Previous filing
03 Apr 2024
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +747 +9.6% 8,524 03 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Award $0 +747 $0.000000 747 03 May 2024 Class A Common Shares 747 Direct F1, F2
transaction KNSA Restricted Share Units Options Exercise $0 -747 -100% $0.000000* 0 03 May 2024 Class A Common Shares 747 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vested immediately upon grant on May 3, 2024; there was no expiration date for the RSUs.